ICAHN School of Medicine At Mount Sinai

Mouse study reveals brain replays and integrates memories, linking negative experiences with past neutral ones, challenging the stability theory of memory formation.

FDA authorizes LumiThera's Valeda Light Delivery System, the first treatment for dry age-related macular degeneration (AMD), using photobiomodulation (PBM) to improve vision. The LIGHTSITE III trial showed significant vision improvement in early AMD patients, with 60% gaining >5 letters in best corrected visual acuity (BCVA).

Scientists at Icahn School of Medicine discovered ovarian cancer tumors produce interleukin-4 (IL-4) to resist immunotherapy, suggesting IL-4 blocking drugs could enhance immunotherapy for ovarian cancer.

Mount Sinai study shows heart signals brain via immune system to increase sleep post-heart attack, promoting healing and reducing inflammation. Mice models and human studies confirm increased sleep, with poor sleepers at higher risk of second heart attack and slower recovery.

New study in NEJM suggests early minimally invasive heart valve replacement for asymptomatic severe aortic stenosis halves hospitalization risk, challenging conventional watch-and-wait approach.

Karyopharm to host investor event on Oct 31, 2024, featuring KOLs Dr. Raajit Rampal and Dr. John Mascarenhas, with a favorable study design update on the Phase 3 SENTRY study in JAKi naive myelofibrosis.

J&J and Eli Lilly revealed efficacy of their IL-23 inhibitors, Tremfya and Omvoh, in treating Crohn’s disease, with both drugs showing significant clinical and endoscopic remission rates in Phase III trials. Both companies aim for FDA approval, with Tremfya already approved for UC, plaque psoriasis, and psoriatic arthritis, while Omvoh is superior to Stelara in treating Crohn's disease. GlobalData predicts Tremfya sales to reach $8.4bn by 2030, surpassing Omvoh's projected $867m.

J&J and Eli Lilly revealed efficacy data for their IL-23 inhibitors, Tremfya and Omvoh, in treating Crohn’s disease, with both drugs aiming for FDA approval. Tremfya showed 60-66.1% clinical remission rates at 48 weeks, while Omvoh achieved 81% clinical and 82% endoscopic remission after two years. GlobalData forecasts Tremfya sales to reach $8.4bn by 2030, surpassing Omvoh's projected $867m.

Subcutaneous infliximab (Zymfentra) maintained efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) patients regardless of immunosuppressant use over 2 years, with no significant differences in clinical remission rates between monotherapy and combination therapy at 54 or 102 weeks. Safety profiles were similar, and higher infliximab levels in combination therapy did not impact efficacy.